The modification of the pre-mRNA cis-splicing process employing a pre-mRNA trans-splicing molecule (PTM) is an attractive strategy for the in situ correction of genes whose careful transcription regulation and full-length expression is determinative for protein function, as it is the case for the dysferlin (DYSF, Dysf) gene. Loss-of-function mutations of DYSF result in different types of muscular dystrophy mainly manifesting as limb girdle muscular dystrophy 2B (LGMD2B) and Miyoshi muscular dystrophy 1 (MMD1). We established a 3′ replacement strategy for mutated DYSF pre-mRNAs induced by spliceosome-mediated pre-mRNA trans-splicing (SmaRT) by the use of a PTM. In contrast to previously established SmaRT strategies, we particularly focused on the identification of a suitable pre-mRNA target intron other than the optimization of the PTM design. By targeting DYSF premRNA introns harbouring differentially defined 3′ splice sites (3′ SS), we found that target introns encoding weakly defined 3′ SSs were trans-spliced successfully in vitro in human LGMD2B myoblasts as well as in vivo in skeletal muscle of wild-type and Dysf −/− mice. For the first time, we demonstrate rescue of Dysf protein by SmaRT in vivo. Moreover, we identified concordant qualities among the successfully targeted Dysf introns and targeted endogenous introns in previously reported SmaRT approaches that might facilitate a selective choice of target introns in future SmaRT strategies.
Introduction
The dysferlin (DYSF, Dysf ) gene is a member of the ferlin gene family encoding the characteristic multiple tandem C2 domains and C-terminal transmembrane domain (1, 2) besides the uncharacterized Fer and DysF domains occurring in ferlins (3) . Dysferlin localizes to the T-tubule system and the plasma membrane of skeletal muscle cells, the so-called sarcolemma, and to intracellular membranous vesicles (4) (5) (6) (7) . Besides skeletal muscles, approach applicable to repair various portions of the DYSF openreading frame. The present knowledge of Dysferlin function still limits the determination of negligible protein domains for the establishment of broad exon excision or protein curtailing therapeutic strategies. A Mini-Dysferlin was shown to rescue the defect in membrane repair, but not the progression of muscular dystrophy in mice (20, 21) . Further, overexpression of DYSF in the murine animal model induces progressive myopathy (22) which excludes the possibility of classic full-length gene replacement therapy and points out that therapeutic dysferlin expression needs careful regulation. Spliceosome-mediated pre-mRNA trans-splicing (SmaRT) (23) integrates these crucial aspects for DYSF repair. The spatiotemporal transcription regulation of the gene is preserved by targeting the transcribed premRNA, and the excision of exon sequence is avoided by replacing 5′ or 3′ pre-mRNA terminus, thus facilitating full-length mRNA expression. Most effective reported SmaRT approaches have been replacements of 3′ pre-mRNA termini (24) (25) (26) (27) (28) (29) (30) (31) that incorporated the simulation of transcription termination in contrast to simulating transcription initiation in 5′ pre-mRNA replacement (32) . As an initial approach, we aimed at establishing a therapeutic SmaRT strategy to replace the DYSF 3′ pre-mRNA moiety.
By using an engineered pre-mRNA trans-splicing molecule (PTM) (23) , the cis-splicing of an appointed endogenous premRNA target intron (TI) can be manipulated to provoke SmaRT. The endogenous pre-mRNA is spliced together at a chosen TI with the exogenous mutation-free mRNA sequence presented by the PTM coding domain in trans to replace the mutated 5′ or 3′ pre-mRNA terminus. Established PTM designs applied in successful therapeutic SmaRT strategies that have resulted in protein rescue (24) (25) (26) (27) (28) (29) (30) (31) comprise three essential domains: (i) binding domain, (ii) splicing domain and (iii) coding domain. For 3′ pre-mRNA replacement, the PTM-binding domain encodes an antisense sequence (AS) complementary to the endogenous TI upstream of the 3′ pre-mRNA portion to be replaced. The PTM splicing domain and the coding domain are thereby localized to the site of the TI cis-splicing process. The PTM splicing domain encodes conserved intron internal splicing signals including the branch point sequence (BP), the poly-pyrimidine tract (PPT) and the 3′ SS AG-dinucleotide, motifs initially recognized on the intron internal 3′ SS region by splicing factor 1/mammalian branch point bridging protein (SF1/mBBP), U2 spliceosomal uridine-rich small nuclear ribonucleoprotein (U snRNP) and U2 auxiliary factors 65 and 35 (U2AF65 and 35) during spliceosome assembly (33) (34) (35) . In feasible SmaRT approaches, the recognition of the PTM 3′ SS by the spliceosome is promoted over the recognition of the endogenous TI 3′ SS, resulting in a spliceosome assembly on the PTM 3′ SS and the induction of the trans-splicing event.
To design a feasible SmaRT strategy for endogenous human DYSF and murine Dysf pre-mRNA, we particularly focused on the identification of pre-mRNA TIs whose cis-splicing could preferentially be manipulated by a PTM. The initial recognition of intron internal 5′ and 3′ SS in cis-splicing of metazoan introns is regulated by serine/arginine-rich proteins (SR-proteins) among other heterogenous nuclear ribonucleoproteins (hnRNPs) which bind exon splice enhancer (ESE) and exon splice silencer (ESS) sequence motifs, directing the exon/intron boundary recognition by exon definition (36) (37) (38) (39) . Therefore we hypothesized that TI susceptibility to trans-splicing depends on the strength of the TI internal 3′ SS and the activity of ESE and ESS signals of the downstream following exon (36) (37) (38) . The presence of ESE and ESS motifs is predictable by the use of sequence analysing algorithms, whereas these predictions are still restricted regarding the determination of the activity of a predicted motif (40, 41) and therefore do not allow evaluation of their actual impact on the splicing process. We chose a test set of four DYSF TIs encoding differentially strong 3′SSs and evaluated the activity of exon internal splicing signals of their downstream exons experimentally. In human LGMD2B patient myoblasts, we detected that SmaRT of DYSF pre-mRNA was feasible at DYSF TIs encoding weakly defined 3′ SSs by low 3′SS strength. trans-Splicing was most efficient at DYSF TI 31 whose downstream exon indicated a limited activity of exon internal splicing signals. By rAAV delivery we applied functional PTMs in vivo on murine Dysf TI counterparts and could detect Dysf protein rescue, albeit at a moderate level. Finally, we analysed sequences of TIs and their downstream exons addressed in previously reported SmaRT strategies and point out that in SmaRT strategies leading to protein rescue TI 3′ SSs were weakly defined by low 3′ SS strength (26, 31) or mutated TI downstream exons (24, 30) . We propose that the identified coherences allow for strategic TI choice in future SmaRT approaches.
Results
Defining a test set of dysferlin pre-mRNA trans-splicing TIs
To replace the 3′ moiety of DYSF pre-mRNA, we chose a test set of TIs located centrally on the human DYSF open-reading frame. We chose DYSF introns 30, 35 and 36 whose 3′ SS strength was ranked by differentially high maximum entropy (MaxEnt) scores using the MaxEntScan::score3ss algorithm (42) (Fig. 1A) . DYSF TIs 30, 35 and 36 were chosen as they lie outside of identified functional dysferlin protein domains that we attributed with strong canonical splicing regulation. We further included DYSF intron 31 in the TI test set as its cis-splicing was shown to be highly susceptible to manipulation before (43) . The 3′ SSs of DYSF TI 31 and 35 were ranked by the lowest MaxEnt scores (4.44 and 4.57) among the chosen DYSF TIs 30, 31, 35 and 36 (Fig. 1A) . Only the DYSF TI 31 sequence deviated from the consensus metazoan 3′ SS sequence, wherein nucleotide position −3 is encoded by a pyrimidine (44) .
To evaluate the activity of splicing signals encoded by the downstream exon of each TI during cis-splicing, we tested the feasibility of these exons to be skipped by masking only their 3′ exon/intron boundary. For simplification, we referred to the TI downstream exon as exon Ey (Fig. 1B) . Antisense-oligonucleotide (AON) 20mers were designed complementary to the DYSF premRNA masking the last three nucleotides of each respective exon Ey and the 5′ SS of the following intron. Hereby, we excluded the 5′ SS signal from exon Ey exon definition and analysed the combination of TI 3′ SS strength and activity of ESEs and ESSs encoded by exon Ey (Fig. 1B) . For simplification, we called the exon upstream of the TI Ex and the next downstream exon Ez (Fig. 1B) . If the TI possessed a strong 3′ SS and the downstream exon Ey encoded strongly active ESEs, at AON application, exon Ey was expected to be linked canonically to the upstream exon Ex. The application of AONs targeting downstream exons Ey of DYSF TIs 30, 31, 35 and 36 was performed in immortalized human control myoblasts (45) encoding an unmutated DYSF sequence in order to exclude any impact of mutations on the splicing process. AON application led to exon Ey-skipping in the case of DYSF TI 31 shown by the detected additional DYSF amplicon of 674 bp (Fig. 1B) . In addition to the low MaxEnt score given for the DYSF TI 31 3′ SS and its unconserved sequence composition, this finding suggested weakly active ESEs encoded by the DYSF TI 31 downstream exon Ey (DYSF exon 32). Therefore, we assumed DYSF TI 31 cis-splicing to be particularly susceptible to manipulation by a PTM.
Weakly defined TI 3′ SSs facilitate accessibility for DYSF 3′ pre-mRNA replacement by a PTM [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] . Coding domains included an influenza hemagglutinin-tag (HA-tag) to facilitate differentiation between cis-and trans-spliced versions of the DYSF mRNA transcript ( Fig. 2A) . The PTM coding domain of human DYSF mRNA sequence was not optimized with the intention to leave its recognition by hnRNPs unmodified (39) and to avoid induction of strong PTM self-translation. The PTM splicing domain 3′ SSs combined with the first exon of PTM coding domains all encoded sequences ranked by higher MaxEnt scores than the endogenous TI 3′ SSs (Fig. 1A) according to the intention of promoting PTM recognition by the spliceosome over the TI splicing motifs. For each PTM, we designed two different ASs as PTM-binding domains. The AS1 was designed to bind ∼200 nucleotides downstream of the TI 5′ SS, thus localizing the PTM 3′ SS in closer proximity to the active spliceosomal U1 snRNP (U1) than the endogenous TI 3′ SS ( Fig. 2A) . The AS2 was designed to mask the endogenous BP, PPT and 3′ SS of the TI to promote the PTM splicing domain instead. (Fig. 1B) . All ASs were designed at a length of ∼150 nucleotides as in a previous functional SmaRT strategy conducted in the laboratory (31 35 or 36 spanning the boundary between exons 35 and 36 or exons 36 and 37, respectively. The efficient expression of each PTM following LV transduction was analysed using the primers E48F and HA-tagR to amplify all transcripts expressed by the LV-PTMs. The overall presence of human DYSF transcript, including cis-and trans-spliced versions, was detected using the DYSF-specific E30F/E40R primer set.
trans-Spliced human DYSF transcript was detected following myoblast transduction by PTM 31.1 and 31.3 both targeting TI 31, whereas transcripts trans-spliced by PTM 31.3 was detected faintly (Fig. 2B ). As well targeting of TI 35 by PTM 35.1 led to DYSF trans-splicing (Fig. 2B ). Both findings were in analogy with the low MaxEnt rankings of DYSF TI 31 and TI 35 3′ SSs and exon-skipping experiments ( Fig. 1A and B) , as detected trans-spliced transcripts junction and wild-type exon 38 sequence were confirmed by sequencing of amplicons obtained using E30F/HA-tagR and E35F/HA-tagR primer sets for DYSF transsplicing detection. Arrows indicate repaired nucleotide in DYSF exon 38 sequence after trans-splicing.
indicated slightly more efficient trans-splicing by PTM 31.1 than by PTM 35.1 (Fig. 2C ). PTMs were approximately equally expressed and the overall expression of human DYSF transcript was detected at comparable levels in all transductions (Fig. 2B) , showing that all PTMs were analysed under comparable conditions. Sequencing of the detected trans-spliced transcripts showed a continuous sequence with the precise intact boundary between trans-spliced endogenous and exogenous DYSF sequence at DYSF exons 31 and 32 after PTM 31.1 and PTM 31.3 transduction. The exact intact boundary was shown as well between exons 35 and 36 following transduction of PTM 35.1. All sequences revealed the wild-type sequence of DYSF exon 38 introduced in trans-spliced transcripts by the PTM coding domains replacing the mutated exon 38 present in cis-spliced IM DYSF1 DYSF transcripts (Fig. 2D) .
Dysferlin pre-mRNA repair at corresponding murine Dysf TIs following rAAV-mPTM injection As a prerequisite for the transfer of the designed strategy to the murine in vivo model, we analysed murine counterpart TI (mTI) 3′ SSs of mTIs 30, 31, 35 and 36 by the MaxEntScan::score3ss algorithm (Fig. 3A) . As found in the human TI test set, mTIs 31 and 35 were ranked by the lowest MaxEnt scores (0.29 and 4.24) and the mTI 31 sequence, like TI 31, encoded a pyrimidine at position −3 deviating from the metazoan consensus 3′ SS sequence (Fig. 3A) . We consequently constructed PTMs 31.1, 31.3 and 35.1 with ASs complementary to murine Dysf introns (mAS) (mPTMs) binding mTIs at intron internal positions as described for the human AS1 and AS3 ( Fig. 2A) . The splicing domain as well as the respective coding domain of DYSF mRNA sequence in mPTMs was identical to PTMs applied on human DYSF pre-mRNA in IM DYSF1 myoblasts.
Recombinant adeno-associated viruses (rAAV2/1) known for their high muscle tropism (47, 48) were produced expressing mPTM 31.1, mPTM 31.3 and mPTM 35.1. We injected tibialis anterior (TA) skeletal muscles of 4 months old C57BL/6 mice with rAAV2/1-mPTM 31.1 (5E + 11 vg/ml), rAAV 2/1-mPTM 31.3 (6E + 11 vg/ml) and rAAV2/1-mPTM 35.1 (2E + 12 vg/ml) and analysed for Dysf trans-splicing 4 weeks following the injection. To detect trans-splicing of murine Dysf pre-mRNA, nested RT-PCR was performed on total RNA extracts employing murine Dysf-specific forward primer mE30Fi and human DYSF-specific reverse primer hE37R as internal primers. These primers amplified the portion of trans-spliced transcripts including the intact boundary between murine exon 31 (mE31) and human exon 32 (hE32) induced by trans-splicing with mPTM 31.1 and mPTM 31.3, as well as the intact boundary of murine exon 35 (mE35) and human exon 36 (hE36) resulting from trans-splicing by mPTM 35.1 (Fig. 3B) . The expression of all mPTMs in injected C57BL/6 muscles was detected by RT-PCR on total RNA using the indicated m48F/HAtagR primer set. The endogenous cis-spliced Dysf transcript was detected using the Dysf-specific primers mE30F and mE40R. trans-Spliced Dysf transcripts were detected in all injected C57BL/6 TAs expressing mPTM 31.1, mPTM 31.3 and mPTM 35.1 (Fig. 3B) . The trans-splicing events were confirmed by direct sequencing of detected amplicons and showed the respective precise boundaries of the Dysf/DYSF chimeras (Fig. 3D) . As observed for trans-splicing of DYSF pre-mRNA in human myoblasts, the mPTM 31.1 and mPTM 35.1, both encoding AS1 addressing the respective TI in 5′ SS proximity, led to detection of a stronger amplicon of trans-spliced transcript than mPTM 31.3 targeting the following intron (Fig. 3B) on total RNA using the Dysf-specific forward primer mE30F and the DYSF-specific reverse primer hE40R to detect Dysf/DYSF chimeras (Fig. 3C) . As in treated C57BL/6 TAs, we detected stronger amplicons of trans-spliced transcripts targeting mTI 31 by mPTM 31.1 than targeting mTI 35 by mPTM 35.1. The injection of rAAV-PTM ΔAS led to no trans-splicing at a level of PTM expression (HemiF/hE37R) comparable to that of both functional mPTMs (Fig. 3C ). All injected mice were homozygous Dysf −/− animals and no endogenous Dysf transcript could be detected by RT-PCR using a reverse primer against the deleted gene region (mE54R). Detected trans-spliced Dysf transcripts were sequenced exhibiting intact chimeras of the murine Dysf and human DYSF sequence comprising the respective exact boundary between murine and human sequence (Fig. 3D) . We could show that in injected muscles of Dysf −/− mice 3′ mRNA replacement of the Dysf pre-mRNA by mPTM 31.1 and mPTM 35.1 lacking the HA-tag facilitated dysferlin rescue. We detected dysferlin expression correctly localized to the sarcolemma by fluorescence immunostaining on transversal TA-sections, albeit in regionally limited groups of myofibres (Fig. 4A) . In muscles injected with mPTM 31.1 ∼6% (n = 6; 141 ± SEM14-positive fibres out of 2407 ± SEM120) of positive myofibres, whereas in muscles injected by mPTM 35.1 ∼2% (41 ± SEM5 out of 1905 ± SEM254) of positive myofibres could be detected (two-tailed unpaired Student's t-test, unequal variance *P < 0.05). We further confirmed the presence of the full-length dysferlin protein in these muscles by immunoprecipitation and thereby for the first time showed dysferlin rescue by SmaRT (Fig. 4B ).
Discussion
In this study, we report the establishment of a functional 3′ premRNA replacement strategy for the dysferlin pre-mRNA by SmaRT and for the first time show the feasibility of dysferlin protein rescue by RNA therapy. Among RNA-therapeutic approaches, SmaRT remains the technologically most extensive strategy. However, for congenital diseases caused by mutation of largely uncharacterized proteins not eligible for exon excision or caused by dominant negative mutation, new insights into SmaRT strategy development remains desirable. In previously reported SmaRT strategies for pre-mRNA 3′ replacement of disease-involved genes, the main focus has been laid on the optimization of the PTM design, e.g. its binding, splicing and coding domain, other than on the structure of the targeted pre-mRNA whose cis-splicing was to be manipulated (23, 25, 27, 28, 31, 46) . We investigated trans-splicing strategy establishment from a new perspective and focused on the pre-mRNA TI, in particular, on the impact of TI 3′ SS definition during cis-splicing on susceptibility for PTM manipulation. By testing different ASs, we further advanced the understanding of determining effective binding sites for the annealing of PTMs to the target pre-mRNA. We hypothesised that the crucial step to induce trans-splicing was the recognition of the PTM 3′ SS by the spliceosome in trans, occurring in competition to the TI 3′ SS recognition in cis. Therefore, we tested TIs encoding differentially strong 3′ SSs and performed exon-skipping experiments to experimentally analyse activity of splicing signals of the TI downstream exons. The excision of DYSF TI 31 downstream exon Ey was inducible by 3′ exon/intron boundary masking AONs, suggesting that other splicing signals, like ESEs, contributing to the definition of the excised exon Ey were not strongly active to compensate the weak DYSF TI 31 3′ SS (Fig. 1B) (htau mouse model (49)). The targeted TIs of F8 (25) and SMN2 (27-29) pre-mRNAs encoded relatively strong 3′ SSs and were successfully trans-spliced with PTMs (Table 1) . Notably, transsplicing of both these TIs was investigated in experimental settings where splicing signals of the downstream exon and following intron sequence were either completely disrupted (F8 E16 mouse model (50)) or harboured a mutation encoding an ESS known to induce the predominant exclusion of the exon (51,52; Type 1 SMA patient cells (27) ; Smn −/− ;SMN2 mouse model (29, 53) ). For diseases predominantly caused by single identified mutations, as in the CFTR gene in cystic fibrosis (54, 55) or in spinal muscular atrophy in the absence of SMN1 gene expression (56) , the inclusion of this condition in the development of a 3′ premRNA replacement strategy is reasonable (24, (27) (28) (29) . For dysferlinopathies, in which disease-causing mutations are scattered over the entire gene (18, 19) , it is crucial to establish 3′ premRNA replacing SmaRT independent of mutations and ESSs known to impact cis-splicing. Accordingly, we established our strategy in experimental settings where TI downstream exons did not encode mutations or known ESSs.
The TIs we successfully targeted by PTMs in our study were relatively short introns as were introns targeted in previous studies that were as well followed by unmutated downstream exons (Table 1) . These introns commonly encoded low-ranked 3′ SSs. It has been observed before that strong intron internal splicing signals can be found more frequently in short introns than in long introns, where exon definition plays a more crucial role and led to the assumption that they were more essential for precise splicing of short introns (37, 42) . Coherent with our findings, this suggests that weak TI 3′ SSs are particularly contributing to trans-splicing susceptibility in short TIs.
PTM ASs binding TIs in 5′ SS as well as in 3′ SS proximity have led to successful trans-splicing in previous SmaRT approaches (Table 1) , which led us to test each PTM with two different binding domains while keeping the PTM design classic by adopting splicing domain and spacer composition from previous SmaRT strategies (23, 46) . Successful trans-splicing of the DYSF and Dysf pre-mRNA was feasible in both TIs by the respective AS1 binding domain targeting in proximity of the U1snRNP binding site at the 5′ SS. We intended to facilitate PTM integration into the splicing process by steric proximity of TI 5′ SS and PTM 3′ SS. The here existent steric proximity of PTM and TI 5′ SS could be a strong argument with regard to the limited length of the spacer sequence (30 nt) included in PTMs between the binding and coding domains. However, trans-splicing has as well been feasible at large TIs by PTMs binding to the 3′ SS of the TI ( Table 1) , showing that steric organization of the intron lariat is as well feasible during PTM-induced trans-splicing. In contrast, masking the TI 3′ SS region by AS2 did not lead to trans-splicing. In previous approaches by others, ASs addressing the TI in 3′ SS proximity were functional when exon internal splicing signals of the downstream exon were restricted (Table 1) (24, 25, (27) (28) (29) (30) raising the assumption that the AS2 binding position might be feasible when spliceosome assembly at the endogenous TI 3′ SS is not actively induced by downstream ESEs. At TIs followed by unmutated downstream exons encoding intact ESEs, only ASs addressing the TI 5′ SS region facilitated trans-splicing (Table 1) (26,31,present study) . Lastly, we designed AS3 masking the DYSF exon 32 5′ SS to simultaneously suppress exon 32 cis-splicing and thus support transsplicing. However, AS3 induced only rare trans-splicing events, which might be due to a steric disadvantage of the PTM 3′ SS being in greater distance and thus less available to the TI 5′ SS. As evidenced in several previous trans-splicing strategies (23, 25, 30) , we could confirm the general necessity of the AS binding domain in PTMs for precisely targeted trans-splicing by showing the absence of trans-splicing following PTM ΔAS application.
We demonstrated feasibility of dysferlin protein rescue by SmaRT, even though at a moderate level. A low efficiency of therapeutic trans-splicing of endogenous pre-mRNAs in vivo, resulting in low levels of protein rescue, has been a drawback of the most present SmaRT strategies (24) (25) (26) 30, 31) . Besides TI choice and PTM design, an aspect influencing efficiency has been shown to be the availability of the TI and the PTM in the splicing reaction. Both TIs and PTMs extra-chromosomally expressed as minigenes, often led to much higher trans-splicing efficiency than the application of the same strategy on endogenous pre-mRNA effectively allowed (23, 27, 30, 31) . This led us to exclusively target endogenous pre-mRNA in our approach. Availability of TIs and PTMs has as well been suggested to decrease specificity of the trans-splicing reaction in the case of an over-representation of target pre-mRNA or PTM (57). We did not detect products of unspecific trans-splicing events in our study. cisSpliced dysferlin transcripts and PTM transcripts were detected at comparable levels following PTM delivery, indicating that an over-representation of pre-mRNA target or PTM was not present in our experimental conditions. A major role in trans-splicing efficiency possibly also plays the size and splicing signal structure of the PTM coding domain. As an exogenous sequence, it is introduced into the endogenous pre-mRNA, which as an artificially generated mRNA molecule undergoes nuclear processing and export. We did not engineer the sequence of the large coding domains of the here applied PTMs but included the endogenous DYSF mRNA sequence to at least partly retain recognition by the nuclear hnRNP-machinery within exon internal sequence (39, 58) . In the very efficient SmaRT strategies developed for SMN2 pre-mRNA (27) (28) (29) , the applied PTM coding domain encodes a single exon preceded by the PTM splicing domain and followed by a poly(A)-signal. The trans-splicing of this coding domain allows intact endogenous exon definition, transcription termination and nuclear export of the generated mRNA molecule. Introduced multiple-exon PTM coding domains do not undergo nuclear pre-mRNA-processing as they lack introns, which might contribute to the constricted translation of this type of trans-spliced mRNA transcript. It was shown in vitro that the introduction of an artificial intron following the first exon of the PTM coding domain increased trans-splicing efficiency on RNA level (31, 59) . The impact of intron inclusion remains to be determined on the protein level, which however is not always feasible with regard to packaging size limits of transgene delivery systems like rAAV (60) . A suggestion has also been that self-translation of the PTM itself from artificial start-codons could have a titrating effect on trans-splicing efficiency (61). We as well detected self-translation of the applied PTMs (Fig. 4B) , however both PTMs led to trans-splicing of endogenous pre-mRNA and the rescue of the dysferlin protein, wherein intensity of protein rescue and PTM self-translation correlated. The suppression of all PTM self-translation yet remains an aspect of great interest in the development of SmaRT strategies for dominant negative mutations.
Materials and Methods

Bioinformatic analysis of intron internal 3′ splice sites
Evaluation of 3′ SSs was performed using the MaxEntScan::score3ss algorithm (http://genes.mit.edu/burgelab/maxent/Xmaxentscan_ scoreseq_acc.html) ranking intron internal 3′ SS sequences ( position −20 to +3) by a motif modelling approach based on the maximum entropy principle (MaxEnt) (42) . The highest value ever given to a 3′ SS was MaxEnt ∼14 (42).
PTM constructs
For PTM expressing constructs, DYSF cDNA sequences were amplified to human DYSF cDNA (identical to NM_003494.2; gift from Dr Steven Laval, Newcastle Upon Tyne, UK) by PCR integrating the described splicing sequences (23) and the influenza hemagglutinin tag (HA-tag). Amplicons were purified and subcloned into pSMD2 (62) after Kpn1 and EcoR1 digestion. ASs were amplified on human genomic DNA (according to NG_008694.1) integrating the PTM spacer sequence and splicing signals as described (23, 46) . For trans-splicing of human intron 30, AS1 was complementary to nucleotide positions +604 to +761, AS2 -150 to −1; for human intron 31, AS1 +211 to −188, AS2 -96 to −1, AS3 +3 of exon 32 to +137 of human intron 32; for human intron 35, AS1 +383 to +533, for AS2 −150 to −1; for human intron 36, AS1 +549 to +709, AS2 −153 to −1. AS amplicons were purified and subcloned into the respective pSMD2-cDNA construct. For LV production, the entire PTM cassettes were subcloned into pRRLSIN. cPPT.hPGK-MCS.WPRE at the Xba1 site (63) . For the construction of murine PTMs (mPTMs), human DYSF cDNA sequences were amplified on pSMD2-PTM constructs excluding the HA-tag for mPTMs injected in Dysf −/− mice. cDNA sequences were subcloned into pSMD2 and ASs according to intron internal Dysf sequences (NC_000072.5) were subcloned into each respective pSMD2 plasmid. For trans-splicing of murine intron 31, AS1 was complementary to nucleotide positions +266 to −166; for AS3, +3 of exon 32 to +109 of intron 32; and for murine intron 35, AS1 +249 to +368, AS2 −123 to −1. All cassettes integrated into pSMD2 were controlled by a CMV promoter and a poly(A) signal. All constructs were sequenced and quantified using a photospectrometer. Nucleotide numbering is according to www.hgvs.org specifications.
Lentiviral production
VSV glycoprotein G-pseudo-typed LVs were produced by transient quadri-transfection of 293T cells and analysed by quantitative real-time PCR on genomic DNA (64).
Human myoblast culture, transfection and transduction
Human immortalized myoblasts originating from an LGMD2B patient biopsy specimen (IM DYSF1) and human immortalized myoblasts taken from a control individual (IM WT3) (44) were cultured as described (65) . For TI 3′ SS evaluation, myoblasts were transfected with 2′-O-methyl-phosphorothioate RNA AONs (eurogentec) (respective exon internal position −3 to intron internal position +17) following the standard Oligofectamine™ Reagant (Life Technologies) transfection procedure. For in vitro trans-splicing evaluation, myoblasts were transduced at a multiplicity of infection of 3 in 6-well plates in 800 µl of reduced proliferation medium (5% fetal calf serum) directly after their trypsination and were diluted 24 h later with 1200 µl of proliferation medium. Cells were washed and incubated in fresh proliferation medium another 24 h later. Three to five days after transduction, differentiation was induced to drive maximum DYSF pre-mRNA expression by incubation in Opti-MEM (Life Technologies) for 10 days.
Recombinant adeno-associated virus production and animal experiments
Recombinant adeno-associated viral vectors of pseudo-typed serotype 2/1 (rAAV2/1) were produced by a tri-transfection protocol as described (66) . Intramuscular injection of viral particles in phosphate-buffered saline at titres between 5E + 11 and 2E + 13 viral genomes per ml was performed into tibialis anterior skeletal muscles of 4 months old C57BL/6 and Dysf −/− mice (B6.129-Dysf<tm1Kcam>/J) at a volume of 45 µl. Four weeks following the injection, animals were sacrificed, muscles were extracted and snap-frozen in liquid nitrogen-chilled isopentane and stored at −80°C. Successful rAAV delivery was verified by RT-PCR on total RNA extraction of injected muscle, using primer sets E48F/ HAtagR and HemiF/hE37R. All animal experiments were performed under appropriate biological containment according to protocols approved by state institutions.
RNA isolation and reverse transcription-PCR analysis
Total RNA was isolated from human myotubes and frozen mouse muscle using RNeasy Mini Kit ® and RNase-free DNase Set ® (Qiagen).
RNA concentration was quantified using NanoDrop ® technology.
Standardized 300 ng of RNA were reverse-transcribed using SuperScript ® III First-Strand Synthesis SuperMix (Life Technologies) including OligodT primers. Total DYSF transcripts from myotubes were amplified using E30F and E40R PCR primers (Table S1 ). trans-Spliced DYSF transcripts were amplified by the E30F/HA-tagR primer set after trans-splicing by PTMs 30. Total murine Dysf transcripts from C57BL/6 mice were detected using the primer set mE30F/mE40R. trans-Spliced chimeras of Dysf and DYSF after injection of mPTM 31.1, mPTM 31.3 and mPTM 35.1 were detected by nested PCR using the external primers mE30F and hE40R and the internal primers mE30Fi and hE37R. The mPTM expression was analysed using the E48F/ HA-tagR primer set.
Trans-spliced Dysf transcripts from Dysf −/− mice were detected by PCR using mE30F/hE40R primers. Successful delivery of mPTM 31.1 and mPTM 35.1 lacking the HA-tag was detected using the HemiF/hE37R primer set. The Dysf knock-out was verified by PCR using the primer set E48F/mE54R. The murine 18S rRNA transcript was detected in all analysed muscles by m18SF/m18SR. All PCR products were separated by gel electrophoresis in 2% agarose gels supplemented with ethidium bromide and purified using NucleoSpin Gel and PCR Clean Up ® (Macherey and Nagel) before Sanger sequencing.
Immunohistochemistry
Transversal cryo-sections of 10 µm were cut from Dysf −/− mice tibialis anterior muscles and immunostained using Hamlet antidysferlin antibody (Novocastra). For secondary detection, the M.O.M. Basic Kit (Vector Labs) and Cy3-labeled Streptavidin (Jackson ImmunoResearch) were used. Mounted sections were analysed by Zeiss LSM 700 confocal microscope (Carl Zeiss MicroImaging GmbH).
Immunoprecipitation
Full-length dysferlin protein was immunoprecipitated from 500 µg of murine TA lysate using Romeo anti-Dysferlin antibody (Abcam) on Dynabeads Protein A (Life Technologies). Immunoprecipitate was detected by immunoblot using Hamlet anti-Dysferlin antibody (Novocastra). For mPTM 31.1noHA treated TAs 10 µg and for mPTM 35.1noHA treated TAs 30 µg lysate were loaded as input.
